Duke Health Joins with nference to Advance Medical Research and Patient Care

Read more

< Back to All Publications

Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

Aug 19 2021

Clinical data to support the use of bamlanivimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) are needed. 2335 Patients who received single-dose bamlanivimab infusion between November 12, 2020, and February 17, 2021, were compared with a propensity-matched control of 2335 untreated patients with mild to moderate COVID-19 at Mayo Clinic facilities across 4 states. The primary outcome was the rate of hospitalization at days 14, 21, and 28. The median age of the population was 63 years; 47.3% of the bamlanivimab-treated cohort were 65 years or more; 49.3% were female and 50.7% were male. High-risk characteristics included hypertension (54.2%), BMI greater than or equal to 35 (32.4%), diabetes mellitus (26.5%), chronic lung disease (25.1%), malignancy (16.6%), and renal disease (14.5%). Patients who received bamlanivimab had lower all-cause hospitalization rates at days 14 (1.5% vs. 3.5%; risk ratio [RR], 0.41), 21 (1.9% vs. 3.9%; RR, 0.49), and 28 (2.5% vs. 3.9%; RR, 0.63).

Authors:

Ravindra Ganesh, Colin F. Pawlowski, John C. O'Horo, Lori L. Arndt, Richard F. Arndt, Sarah Bell, Dennis M. Bierle, Molly Destro Borgen, Sara Hanson, Alexander Heyliger, Jennifer L. Larsen, Patrick J. Lenehan, Robert Orenstein, Arjun Puranik, Leigh L. Speicher, Sidna M. Tulledge-Scheitel, AJ Venkatakrishnan, Caroline G. Wilker, Andrew D. Badley, and Raymund R. Razonable

nference, Cambridge, MA 02142, USA Mayo Clinic, Rochester, MN 55905, USA

Mayo Clinic

nference

Correspondence to:

Andrew Badley (badley.andrew@mayo.edu)

Let’s talk about how we can work together.

Fill out the form and we’ll get right back to you.